OKYO Pharma Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its innovative drug, urcosimod, for the treatment of neuropathic corneal pain (NCP). This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs. Neuropathic corneal pain is a debilitating condition characterized by severe eye pain due to nerve damage, affecting patients worldwide. OKYO Pharma is committed to advancing urcosimod through clinical development and regulatory review to provide an effective treatment option for this condition. The Fast Track designation allows for more frequent meetings with the FDA, eligibility for Accelerated Approval and Priority Review, and potential Rolling Review of the New Drug Application, which could significantly accelerate the availability of urcosimod to patients.